Key Milestones for Molecular (MTEM) in 2023: accelerating enrollment across all clinical programs; Initiation of first-in-human Phase I study for MT-8421 in 3Q 2023; Advancement of Bristol Myers Squibb (BMY) research collaboration across multiple targets; MTEM expects to provide periodic updates on MT-6402, MT-8421, and MT-0169 throughout 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MTEM:
- Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
- MTEM Earnings this Week: How Will it Perform?
- Indaptus Therapeutics appoints Waltzman as Chief Medical Officer
- Molecular Templates Announces Executive Leadership Changes
- Molecular Templates announces up to $40M private placement offering
